Novel MRI Sequence- MR Fingerprinting
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03722459|
Recruitment Status : Suspended (Study suspended due to COVID-19 restrictions. Study will be resumed once plans for appropriate social distancing are in place.)
First Posted : October 29, 2018
Last Update Posted : June 14, 2021
Magnetic Resonance Imaging (MRI) has become one of most important medical imaging tools over the past 30 years because it is non-invasive, requires no ionizing radiation, and provides exquisite images of soft tissues and anatomic structures with many tissue/disease specific contrasts. While MRI has served the community well for many years, it is increasingly clear that it also has significant limitations.
One of the principle limitations is the lack of quantitative information for tissue/structure characterization. The current paradigm of MRI is to use a set of scanner settings to generate an image "weighted" by a specific MR contrast mechanism (physical parameter), where it is hoped that variations in the parameter will be accentuated. However, without quantitative knowledge of the parameters, the final image contrast may depend on many factors, which complicates image interpretation and diagnostic performance. Quantitative measurement can provide a great deal of information about tissue properties and pathological conditions, since these parameters ultimately determine the contrast that is observed in conventional images.
|Condition or disease||Intervention/treatment||Phase|
|Disease||Device: MR Fingerprinting||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||105 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Novel MRI Sequence- MR Fingerprinting|
|Actual Study Start Date :||November 2, 2018|
|Estimated Primary Completion Date :||December 2021|
|Estimated Study Completion Date :||December 2021|
Experimental: All participants
All participants will receive the investigational MR Fingerprinting sequence.
Device: MR Fingerprinting
The MR fingerprinting technique requires less than 15 minutes and will be added following the standard MRI sequence.
- Percent of Patients with Visible Region of Interest (Imaging Visibility) [ Time Frame: Immediately following MRI completion, within approximately 5 minutes ]MR fingerprinting sequences will be examined to determine their utility for visualizing pathology.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03722459
|United States, North Carolina|
|University of North Carolina at Chapel Hill|
|Chapel Hill, North Carolina, United States, 27599|
|Principal Investigator:||William Hyslop, MD, PhD||University of North Carolina, Chapel Hill|